Aim: This paper aimed to assess and follow up the course of resolved HBV (hepatitis B virus) during and after treatment with direct-acting antiviral drugs (DAAs).
Background: Co-infection with hepatitis B and hepatitis C is increasingly recognized in patients with chronic hepatitis. Resolved HBV in patients with chronic HCV (hepatitis C virus) infection has been investigated during interferon therapy, and the investigators suggest a possible correlation with a lower response to anti-viral treatment, higher grades of liver histological changes, and development of hepatocellular carcinoma.
Methods: Three hundred and thirteen patients were included in our observational and prospective study; two hundred and fifty-three patients had chronic hepatitis C (CHC) (group I), and sixty patients had both CHC and resolved HBV-infection (group II). They all were eligible for treatment with DAAs therapy for chronic HCV in our hepatology unit, Internal Medicine Department, Zagazig University Hospitals from December 2017 to September 2018. They were subjected to thorough history taking, full clinical examination, routine laboratory investigations, HCV antibody, HCV RNA, HBV surface antigen (HBsAg), HBV surface antibody (anti-HBs) HBV core antibody (anti-HBc), and HBV-DNA quantitative levels. All patients were followed up at baseline, at the end of week 4 of anti-viral therapy, at the end of treatment and 12 weeks after treatment.
Results: Assessment at 28 days showed significant decreases in ALT and AST levels in both groups, with stabilization of these levels on follow-up at 12 and 24 weeks. The efficacy of treatment was comparable in both groups. No case of ALT flare was observed in either group. Similar outcomes regarding AST and ALT levels were found in patients with diseases associated with immune derangement.
Conclusion: The risk of resolved HBV reactivation during or after treatment with DAAs is low.
Keywords: HCV infection, Resolved HBV, HBV flare, Direct-acting antivirals.
(Please cite as Mohamed SY, Gaballah BA, Mohamed Elsadek H, Hassan Emara M, Hamed EF. Resolved HBV behavior during the treatment of chronic HCV infection with direct-acting antivirals. Gastroenterol Hepatol Bed Bench 2019;12(4):301-308).
Peeling RW, Boeras DI, Marinucci F, Easterbrook P. The future of viral hepatitis testing: innovations in testing technologies and approaches. BMC Inf Dis 2017;17:699.
Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepatic Med Evidence Res 2015; 7:51.
Tabor E, Hoofnagle J, Smallwood L, Drucker J, Pineda-Tamondong G, Ni L, et al. Studies of donors who transmit posttransfusion hepatitis. Transfusion 1979;19:725-31.
Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepatitis 2002;9:243-57.
Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49:652-7.
Kishk R, Atta HA, Ragheb M, Kamel M, Metwally L, Nemr N. Genotype characterization of occult hepatitis B virus strains among Egyptian chronic hepatitis C patients. East Mediterr Health J 2014; 20:130-9.
Selim HS, Abou-Donia HA, Taha HA, El Azab GI, Bakry AF. Role of occult hepatitis B virus in chronic hepatitis C patients with flare of liver enzymes. Eur J Int Med 2011;22:187-90.
Villa E, Grottola A, Trande P, Seium Y, Rebecchi AM, Dugani A, et al. Reactivation of hepatitis B virus infection induced by interferon (IFN) in HBsAg-positive, antiHCV-positive patients. Lancet 1993;341:1413.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017;66:153-194.
AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932-54.
The U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. Available from: https://www.fda.gov/media/100702/download. [Accessed 2016;17.]
Bessone F, Dirchwolf M. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. World J Hepatol 2016;8:385.
Omar H, El Akel W, Elbaz T, El Kassas M, Elsaeed K, El Shazly H, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real‐world results from 18 378 patients in Egypt. Aliment Pharmacol Ther 2018;47:421-31.
Blach S, Zeuzem S, Manns M, Altraif I, Duberg AS, Muljono DH, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161-76.
Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2018;67:1477-92.
Jeon JW, Kim SM, Cho H, Baek CH, Kim H, Shin S, et al. Presence of Hepatitis B Surface Antibody in Addition to Hepatitis B Core Antibody Confers Protection Against Hepatitis B Virus Infection in Hepatitis B Surface Antigen–negative Patients Undergoing Kidney Transplantation. Transfusion 2018;102:1717-23.
Bersoff-Matcha SJ, Cao K, Jason M, Ajao A, Jones SC, Meyer T, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the US Food and Drug Administration Adverse Event Reporting System. Annals Int Med 2017;166:792-8.
Calvaruso V, Ferraro D, Licata A, Bavetta M, Petta S, Bronte F, et al. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct‐acting antivirals. J Viral Hep 2018;25:72-9.
Gedik H, Parcaoglu F. Chronic Hepatitis B Reactivation Subsequent to Chronic Hepatitis C Treatment: A Case Report. J Hep 2017;3:17.
Londoño MC, Lens S, Marino Z, Bonacci M, Ariza X, Broquetas T, et al. Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti‐viral therapy with an interferon-free regimen. Aliment Pharmacol Ther 2017; 45:1156-61.
Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol 2017; 15:132-6.